Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF: Rebif Morning vs Evening Administration in RMS
NCT02064816Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- May 2014
- Primary completion
- Apr 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 4 trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck KGaA. Started May 2014; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02064816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064816.